Perspectives on margins in DCIS: Pathology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 10, 2010, Pages 1219-1222

  Lester, Susan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinoma in situ; Ductal carcinoma in situ; Lobular carcinoma in situ; Margins; Pathology

Indexed keywords

TAMOXIFEN;

BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER SURVIVAL; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; REVIEW;

EID: 78951472213     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0089     Document Type: Review

References (21)

1. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006;19:617-621.
2. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006;19:1506-1511.
3. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005;103:1778-1784.
4. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-2484.
5. Clingan R, Griffin M, Phillips J, et al. Potential margin distortion in breast tissue by specimen mammography. Arch Surg 2003;138:1371-1374.
6. Graham RA, Homer MJ, Katz J, et al. The pancake phenomenon contributes to the inaccuracy of margin assessment in patients with breast cancer. Am J Surg 2002;184:89-93.
7. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 2009;133:15-25.
8. Faverly DR, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994;11:193-198.
9. Sgroi DC. Preinvasive breast cancer. Annu Rev Pathol 2010;5:193-221.
10. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
11. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;1031-1036.
12. Goldstein NS, Vicini FA, Hunter S, et al. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors. Am J Clin Pathol 2005;123:679-689.
13. Amari M, Moriya T, Ishida T, et al. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast. Jpn J Clin Oncol 2003;33:556-562.
14. Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Int Med 2000;160:953-958.
15. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
16. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999;86:429-438.
17. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with DCIS: an update of the NSABP experience. Semin Oncol 2001;28:400-418.
18. Fisher ER, Land ST, Saad RS, et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol 2007;128:86-91.
19. UKCCCR DCIS Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
20. Kerlikowske K, Molinaro AM, Gautheir ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-637.
21. Schedin P, Borges V. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Res 2009;11:102.